Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17870639 | 0.83 | CA12 (0.44) | CA12CA9MCL1CA1ESR2 | |
| SCHEMBL207520 | 0.74 | CYP2A6 (0.44) | CA12CA9CA1HSD17B10KDM4E | |
| SCHEMBL207632 | 0.74 | MAOB (0.41) | CA12CA9CA1KDM4EALDH1A1 | |
| SCHEMBL146387 | 0.74 | CYP2A6 (0.40) | CA12CA9CA1KDM4EALDH1A1 | |
| SCHEMBL4146968 | 0.74 | ALDH1A1 (0.41) | FLT3PTGS1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL5535202 | 0.69 | ALDH1A1 (0.37) | PTGS1HSD17B10KDM4EALDH1A1LMNA | |
| SCHEMBL533282 | 0.69 | CYP2A6 (0.47) | CA12CA9CA1HSD17B10KDM4E | |
| SCHEMBL208879 | 0.69 | CYP1A1 (0.34) | — | |
| SCHEMBL533590 | 0.69 | PIM1 (0.44) | KDM4EMAOAMAOBTSHRMEN1 | |
| SCHEMBL693553 | 0.69 | PGR (0.47) | CA12ESR1ESR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197277-B1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2021-12-22 | — | — | EP | claimed |
| US-20170283439-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CCHDI Foundation Inc. (US) | 2017-10-05 | — | — | US | claimed |
| EP-3197277-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2017-08-02 | — | — | EP | claimed |
| WO-2016033440-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | claimed |
| US-11851446-B2 | Probes for imaging Huntingtin protein | CHDI FOUNDATION, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-3197277-B1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210380608-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2021-12-09 | — | — | US | disclosed |
| CN-107105667-B | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20170283439-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CCHDI Foundation Inc. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-3197277-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016033440-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| EP-1653944-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-11-10 | — | — | EP | disclosed |
| EP-2099442-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-1611088-B1 | HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS INC (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008082856-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1611088-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004092115-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-4222767-A | Certain herbicidal sulfonates and sulfamates | FISONS LIMITED (GB) | 1980-09-16 | — | — | US | disclosed |
| US-4162154-A | BENZOFURAN DERIVATIVES | FISONS LIMITED (GB) | 1979-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851446-B2 | Probes for imaging Huntingtin protein | HTT, HYPK, HSPBP1 | CA12 2572/4885CA9 3467/4885MCL1 3712/4885 |
| US-20210380608-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | CA12 2572/4885CA9 3467/4885MCL1 3712/4885 |
| US-20170283439-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | CA12 2572/4885CA9 3467/4885MCL1 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.